Zhengye Biotechnology Holding (ZYBT) Payables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has 3 years of Payables data on file, last reported at $9.2 million in Q4 2025.

• Payables for Q4 2025 came in at $9.2 million, down 17.15% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.2 million (down 17.15% YoY), and the FY2025 annual result was $9.1 million, down 16.9% from the prior year.
• Payables retreated to $9.2 million in Q4 2025 per ZYBT's latest filing, from $11.2 million in the prior quarter.
• Over five years, Payables peaked at $13.4 million in Q4 2023 and troughed at $9.2 million in Q4 2025.
• A 3-year average of $11.3 million and a median of $11.2 million in 2024 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables declined 16.71% in 2024, then slipped 17.15% in 2025.
• A 3-year view of Payables shows it stood at $13.4 million in 2023, then dropped by 16.71% to $11.1 million in 2024, then fell by 17.15% to $9.2 million in 2025.
• Business Quant data shows ZYBT's Payables at $9.2 million in Q4 2025, $11.2 million in Q2 2025, and $11.1 million in Q4 2024.